Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae

Charles R. Dean; David T. Barkan; Alun Bermingham; Johanne Blais; Fergal Casey; Anthony Casarez; Richard A. Colvin; John Fuller; Adriana K. Jones; Cindy Li; Sara López; Louis E. Metzger; Mina Mostafavi; Ramadevi Prathapam; Dita Rasper; Folkert Reck; Alexey Ruzin; Jacob Shaul; Xiaoyu Shen; Robert L. Simmons; Peter Skewes-Cox; Kenneth T. Takeoka; Pramila Tamrakar; Tsuyoshi Uehara; Jun-Rong Wei

doi:10.1128/aac.01200-18

Abstract

These results support the continued development of LYS228, which is currently undergoing phase II clinical trials for complicated intraabdominal infection and complicated urinary tract infection (registered at ClinicalTrials.gov under identifiers NCT03377426 and NCT03354754).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dean et al. (2018) studied this question.

synapsesocial.com/papers/6a00e6066be84a7ac88591d8 https://doi.org/10.1128/aac.01200-18

View Full Paper

Ask AI

Bookmark

Share

Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae

Abstract

Discussion

Cite This Study

Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Antimicrobial Agents and Chemotherapy

Keep reading

More related papers

More from Antimicrobial Agents and Chemotherapy